

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM358117

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	MERGER		
<b>EFFECTIVE DATE:</b>	12/31/2012		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Jazz Pharmaceuticals (EUSA Pharma USA) Inc.		12/27/2012	CORPORATION: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Jazz Pharmaceuticals (EUSA Pharma) Inc.		
<b>Street Address:</b>	1717 Langhorne-Newtown Road, Suite 201		
<b>Internal Address:</b>	One Summit Square		
<b>City:</b>	Langhorne		
<b>State/Country:</b>	PENNSYLVANIA		
<b>Postal Code:</b>	19047		
<b>Entity Type:</b>	CORPORATION: DELAWARE		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	2048135	PROTASCINT	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	3038630223		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	3038639700		
<b>Email:</b>	mtrudell@sheridanross.com		
<b>Correspondent Name:</b>	Miriam D. Trudell, Sheridan Ross P.C.		
<b>Address Line 1:</b>	1560 Broadway, Suite 1200		
<b>Address Line 4:</b>	Denver, COLORADO 80202		
<b>ATTORNEY DOCKET NUMBER:</b>	5753-32		
<b>NAME OF SUBMITTER:</b>	Miriam D. Trudell		
<b>SIGNATURE:</b>	/Miriam D. Trudell/		
<b>DATE SIGNED:</b>	10/09/2015		
<b>Total Attachments: 4</b>			
source=Jazz Pharmaceuticals (EUSA Pharma USA) Inc merger#page1.tif			
source=Jazz Pharmaceuticals (EUSA Pharma USA) Inc merger#page2.tif			

CH \$40.00 2048135

source=Jazz Pharmaceuticals (EUSA Pharma USA) Inc merger#page3.tif

source=Jazz Pharmaceuticals (EUSA Pharma USA) Inc merger#page4.tif

# Delaware

PAGE 1

*The First State*

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF OWNERSHIP, WHICH MERGES:

"JAZZ PHARMACEUTICALS (EUSA PHARMA USA) INC.", A DELAWARE CORPORATION,


WITH AND INTO "JAZZ PHARMACEUTICALS (EUSA PHARMA) INC." UNDER THE NAME OF "JAZZ PHARMACEUTICALS (EUSA PHARMA) INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE TWENTY-SEVENTH DAY OF DECEMBER, A.D. 2012, AT 3:26 O'CLOCK P.M.


AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF OWNERSHIP IS THE THIRTY-FIRST DAY OF DECEMBER, A.D. 2012, AT 11:58 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.

4104057 8100M

121396780



  
Jeffrey W. Bullock, Secretary of State  
AUTHENTICATION: 0102149

DATE: TRADEMARK  
REEL: 005642 FRAME: 0035

**CERTIFICATE OF OWNERSHIP AND MERGER**

**merging**

**JAZZ PHARMACEUTICALS (EUSA PHARMA USA) INC.**  
(a Delaware Corporation)

**with and into**

**JAZZ PHARMACEUTICALS (EUSA PHARMA) INC.**  
(a Delaware Corporation)

Pursuant to Section 253 of the Delaware General Corporation Law, Jazz Pharmaceuticals (EUSA Pharma) Inc., a corporation organized and existing under and by virtue of the laws of the State of Delaware (the "*Company*"),

**DOES HEREBY CERTIFY:**

**FIRST:** That it was organized pursuant to the provisions of the Delaware General Corporation Law (the "*DGCL*").

**SECOND:** That it owns 100% of the outstanding shares of the capital stock of Jazz Pharmaceuticals (EUSA Pharma USA) Inc., a corporation organized pursuant to the provisions of DGCL (the "*Subsidiary*").

**THIRD:** The Company, by the following resolutions of its Board of Directors (the "*Board*"), duly adopted by unanimous written consent executed as of December 27, 2012, determined to merge the Subsidiary into itself on the conditions set forth in such resolutions (the "*Merger*");

**WHEREAS,** the Company owns all of the issued and outstanding capital stock of Jazz Pharmaceuticals (EUSA Pharma USA) Inc., a Delaware corporation (the "*Subsidiary*"), and has determined it to be in the best interests of the Company and its stockholders to merge the Subsidiary with and into the Company in a statutory short form merger pursuant to the provisions of Section 253 of the Delaware General Corporation Law, in which the Company will be the surviving corporation of such merger.

**NOW, THEREFORE, BE IT RESOLVED,** that Subsidiary, Company's wholly owned subsidiary, shall be merged with and into Company, effective 11:58 p.m. (E.S.T.) on December 31, 2012, with Company being the surviving corporation of such merger and acquiring thereby all the assets and properties of Subsidiary and assuming all of the liabilities and obligations of Subsidiary; and

**RESOLVED FURTHER,** that the officers of the Company, each of them with full authority to act without the others, are hereby authorized and directed, for and on behalf of the Company, to cause the Company to execute and deliver, and file with the Delaware Secretary of State, a Certificate of Ownership and Merger in substantially the form attached hereto as **EXHIBIT A**, with respect to the merger of the Subsidiary with and into the Company, and to execute, deliver and file such additional documents or perform such acts as are determined to be necessary or appropriate to carry out the merger of the Subsidiary into the Company as described above.

**FOURTH:** The name of the surviving corporation following the Merger is Jazz Pharmaceuticals (EUSA Pharma) Inc.

**FIFTH:** Upon the effectiveness of the filing of this Certificate of Ownership and Merger, the Certificate of Incorporation of Jazz Pharmaceuticals (EUSA Pharma) Inc., as amended to date, shall continue to be the certificate of incorporation of said surviving corporation until further amended in accordance with the provisions of the DGCL.

**SIXTH:** The Merger shall become effective at 11:58 p.m. (E.S.T.) on December 31, 2012.

*[SIGNATURE PAGE FOLLOWS]*

